AstraZeneca Shares Plunge After Heart Drug Fails Key Phase III Trial

AstraZeneca (NASDAQ: AZN) shares plunged after the pharmaceutical giant announced its heart and nerve disease drug, Wainua, failed to meet its primary goal in a critical Phase III clinical trial. The setback deals a significant blow to the company's cardiovascular drug pipeline and erases a major potential revenue stream.

Trial Fails Primary Endpoint

The company disclosed that the Phase III CARDIO-TTRansform trial did not show a statistically significant benefit over a placebo. The study evaluated the ability of Wainua (eplontersen), co-developed with partner Ionis, to reduce cardiovascular deaths and recurrent cardiovascular events in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) when added to the existing standard of care.

AstraZeneca noted that a prespecified subgroup analysis showed a nominally significant benefit for patients receiving Wainua as a monotherapy. However, this was not enough to salvage investor sentiment following the failure to meet the trial's primary objective in a competitive treatment landscape.

Financial and Pipeline Impact

Ad

The negative trial result has immediate financial implications for AstraZeneca's growth outlook. According to a note from analysts at Citi, the ATTR-CM indication for Wainua carried projections for peak annual sales of more than $6 billion.

The analysts had estimated the program represented roughly 2.8% of AstraZeneca’s overall valuation. The trial's failure marks a meaningful hit to the company's pipeline, particularly in its cardiovascular franchise.

Market Reaction

In response to the news, AstraZeneca's London-listed shares plummeted 8.8%, hitting a session low of 12,864p. The sell-off was so severe that the stock's decline was a primary factor in pulling the UK's blue-chip FTSE 100 index into negative territory, despite gains in the broader pan-European STOXX 600 index.